At the end of each cycle patients will have testing performed to assess for toxicity and efficacy. A directed questionnaire for neurologic toxicities, review of concomitant medications and other support therapies, including growth factors and transfusions will also be performed. Three months after the last dose of study drug, and every three months thereafter for 2 years, patients are to attend follow-up study visits. At these visits, a physical examination will be performed and Karnofsky performance status assessed. Patients will have a neurological questionnaire completed, have tests for disease assessments including serum and protein electrophoresis with quantification of immunoglobulins and immunofixation studies, Beta2-microglobulin, bone marrow aspirate and biopsy (only if the patient is in a complete remission), CT scanning of the chest, abdomen and pelvis (only if patient had evidence of WM disease on baseline scans). Serum and protein electrophoresis with quantification of immunoglobulins and immunofixation studies must be repeated > 6 weeks if a patient attains a complete response. At the follow-up study visits, a complete blood count plus differential, electrolytes, urea, creatinine, total bilirubin, SGOT, will also be obtained.